Protein Kinases - High Yield Targets for Cancer and Dementia Drug Discovery.

Autor: Shroff R; Department of Medicine, University of Arizona College of Medicine, Tucson., Goetzl EJ; Department of Medicine, University of California Medical Center, San Francisco. Electronic address: edward.goetzl@ucsf.edu.
Jazyk: angličtina
Zdroj: The American journal of medicine [Am J Med] 2024 Nov; Vol. 137 (11), pp. 1055-1058. Date of Electronic Publication: 2024 Jun 24.
DOI: 10.1016/j.amjmed.2024.06.016
Abstrakt: Cellular protein kinases are involved in diverse normal cellular functions. Many types of dysregulation of protein kinases are the molecular basis for development of common cancers and neurodegenerative diseases. More than 80 small-molecule protein kinase inhibitors are available now and approved by the US Food and Drug Administration for successful treatment of cancers and neurodegenerative diseases. Newly designed protein kinase inhibitors and related forms of therapy based on a greater understanding of molecular mechanisms have diminished the appearance of disease resistance to protein kinase inhibitors and other side effects. These advances will further promote the success of protein kinase inhibitors in treatment of common cancers, Alzheimer's disease, and other neurodegenerative conditions.
(Copyright © 2024. Published by Elsevier Inc.)
Databáze: MEDLINE